Quantcast

Latest Prednisone Stories

2009-02-25 07:00:00

- New Progression-Free Survival Data Support Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - - Results To Be Presented at the American Society of Clinical Oncology's 2009 Genitourinary Cancers Symposium - SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the...

2008-12-08 20:32:00

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results based on extended follow up of patients from the large, international Phase III VISTA(1) trial showing continued survival improvement for patients with previously untreated multiple myeloma given VELCADE, melphalan and prednisone (VcMP). The VELCADE combination demonstrated consistent efficacy in all patient sub-groups, including those with poor prognostic characteristics, such as...

2008-10-23 09:00:38

Poniard Pharmaceuticals, a biopharmaceutical company focused on oncology, has announced positive incremental data from its ongoing Phase II clinical trial of picoplatin in combination with docetaxel and prednisone as first-line therapy for metastatic hormone-refractory prostate cancer. The expanded and updated results continued to show that picoplatin can be safely administered with full-dose docetaxel and prednisone, the standard treatment for hormone-refractory prostate cancer (HRPC),...

2008-10-22 15:00:11

U.S. researchers say the use of modern immunosuppressive drugs eliminates the need for steroid therapy as early as seven days following a kidney transplant. Dr. Steve Woodle of the University of Cincinnati, who led the study, said elimination of a daily dose of steroids following transplantation minimizes chronic health conditions common to kidney transplant recipients. "Steroids have long been the primary source of morbidity and complications following successful kidney transplantation,"...

2008-10-16 09:00:10

Cell Genesys, Inc. (Nasdaq:CEGE) today announced its decision to terminate the VITAL-1 Phase 3 clinical trial of GVAX immunotherapy in patients with asymptomatic metastatic hormone-refractory prostate cancer. The trial was fully enrolled in 2007 with 626 patients and compared GVAX immunotherapy to Taxotere(R) (docetaxel) chemotherapy plus prednisone. The Company terminated the trial based on the results of a previously unplanned futility analysis conducted by the study's Independent Data...

2008-09-18 15:00:12

DEAR DR. DONOHUE: I am a 78-year-old male who recently experienced a breaking out on my face and around my nose. Pimples came up. My physician diagnosed it as rosacea. He prescribed tetracycline and MetroGel ointment. The area cleared up. I wonder if I can stop taking the prescriptions. Perhaps you might explain what rosacea is. - O.L. ANSWER: Rosacea (rose-A-shuh) can happen to anyone, but it particularly singles out people who were or are prone to blush easily. The tip of the nose, the...

2008-08-27 18:00:17

CAMBRIDGE, Mass., Aug. 27 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced the publication of results from the 682 patient, randomized, Phase III VISTA(1) trial in this week's edition of the New England Journal of Medicine. The results showed a significant survival benefit and a 30 percent complete remission (CR) rate with VELCADE, melphalan and prednisone (VcMP) compared to 4 percent for melaphalan and prednisone (MP) alone in previously untreated multiple myeloma...

2008-08-27 09:00:23

Cell Genesys, Inc. (Nasdaq:CEGE) today announced that it has terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in combination with Taxotere(R) (docetaxel) to Taxotere plus prednisone in patients with advanced-stage prostate cancer. The Company ended the trial as recommended by its Independent Data Monitoring Committee (IDMC) which, in a routine safety review meeting held this week, observed an imbalance...

2008-08-27 06:00:48

ImClone Systems has announced that its disease-directed Phase II clinical trial in patients with advanced prostate cancer randomized to treatment with either IMC-A12 or IMC-1121B plus mitoxantrone and prednisone has commenced patient enrollment. This multicenter, randomized open-label Phase II single-arm study is enrolling patients with metastatic androgen-independent prostate cancer who have developed disease progression during or within 60 days of receiving docetaxel-based chemotherapy or...

2008-08-26 09:00:28

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed Phase 2 clinical trial in patients with advanced prostate cancer randomized to treatment with either IMC-A12 or IMC-1121B plus mitoxantrone and prednisone has commenced patient enrollment. IMC-A12 and IMC-1121B are two therapeutic candidates in ImClone's proprietary receptor-targeted antibody pipeline. IMC-A12 is...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.